Optimal Duration of Anticoagulation Therapy for Low-risk Pulmonary Embolism Patients With Cancer

PHASE4CompletedINTERVENTIONAL

Enrollment

179

Participants

Timeline

Start Date

February 18, 2021

Primary Completion Date

September 27, 2024

Study Completion Date

December 31, 2024

Conditions

Venous ThrombosisNeoplasmsAnticoagulants

Interventions

DRUG

Long DOAC

Administration of Rivaroxaban for 18 months

DRUG

Short DOAC

Administration of Rivaroxaban for 6 months

Trial Locations (1)

Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto

All Listed Sponsors

collaborator

Bayer Yakuhin, Ltd.

INDUSTRY

lead

Takeshi Morimoto

OTHER

NCT04724460 - Optimal Duration of Anticoagulation Therapy for Low-risk Pulmonary Embolism Patients With Cancer | Biotech Hunter | Biotech Hunter